ES2527226T3 - Nuevo derivado fenilpiridina y agente médico que comprende el mismo - Google Patents

Nuevo derivado fenilpiridina y agente médico que comprende el mismo Download PDF

Info

Publication number
ES2527226T3
ES2527226T3 ES10820125.2T ES10820125T ES2527226T3 ES 2527226 T3 ES2527226 T3 ES 2527226T3 ES 10820125 T ES10820125 T ES 10820125T ES 2527226 T3 ES2527226 T3 ES 2527226T3
Authority
ES
Spain
Prior art keywords
group
formula
following formula
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10820125.2T
Other languages
English (en)
Inventor
Toru Miura
Seiichi Sato
Hajime Yamada
Junya TAGASHIRA
Ryohei Sekimoto
Rie Ishida
Hitomi Aoki
Tadaaki Ohgiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Application granted granted Critical
Publication of ES2527226T3 publication Critical patent/ES2527226T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto representado por la fórmula (I) siguiente, o una sal del mismo,**Fórmula** o un solvato del mismo: en la fórmula, el anillo A representa la fórmula siguiente (II), o la fórmula siguiente (III):**Fórmula** el anillo B representa la fórmula siguiente (IV), o la fórmula siguiente (V):**Fórmula** X representa C-R5 o un átomo de nitrógeno, R1 representa un grupo alquilo de C1-6, R2 representa un grupo alquilo de C1-6, o un grupo cicloalquilo de C3-8, R3, R4, y R5 representan, independientemente unos de otros, un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo de C1-6, un grupo haloalquilo de C1-6, o un grupo alcoxi de C1-6, en el que el grupo alcoxi de C1-6 puede estar substituido con uno hasta el número más grande posible de grupos substituyentes seleccionados entre el grupo que consiste en un grupo fenilo; un grupo hidroxilo; un grupo alcoxi de C1-6; un grupo alquiltio de C1-6; un grupo alquilsulfonilo de C1-6; un grupo oxazolilo (el cual puede estar substituido con un grupo heteroarilo de 5 a 10 átomos, el cual puede estar substituido con un grupo alquilo de C1-6; un grupo arilo de C6-10; o un átomo de halógeno); un grupo piridilo (el cual puede estar substituido con un grupo alquilo de C1-6);un grupo alcoxicarbonilo de C1-6; un grupo carboxilo; un grupo carbamoilo; un grupo monoalquilcarbamoilo de C1-6; un grupo dialquilcarbamoilo de C1-6; un grupo alcanoilami20 no de C1-6; un grupo alquilsulfonilamino de C1-6; un grupo haloalquilsulfonilamino de C1-6; un grupo amida; y un grupo sulfonamida.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES10820125.2T 2009-09-29 2010-09-29 Nuevo derivado fenilpiridina y agente médico que comprende el mismo Active ES2527226T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009223887 2009-09-29
JP2009223887 2009-09-29
PCT/JP2010/005842 WO2011040004A1 (ja) 2009-09-29 2010-09-29 新規なフェニルピリジン誘導体及びこれを含有する医薬

Publications (1)

Publication Number Publication Date
ES2527226T3 true ES2527226T3 (es) 2015-01-21

Family

ID=43825849

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10820125.2T Active ES2527226T3 (es) 2009-09-29 2010-09-29 Nuevo derivado fenilpiridina y agente médico que comprende el mismo

Country Status (10)

Country Link
US (1) US8778954B2 (es)
EP (1) EP2484675B1 (es)
JP (1) JP5583681B2 (es)
KR (1) KR20120095370A (es)
CN (1) CN102639527B (es)
DK (1) DK2484675T3 (es)
ES (1) ES2527226T3 (es)
PT (1) PT2484675E (es)
TW (1) TWI500611B (es)
WO (1) WO2011040004A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2687523T3 (en) * 2011-03-14 2016-03-14 Kowa Co New phenylpyridinderivat and pharmaceutical containing this

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
EP0514192A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5212177A (en) * 1991-12-16 1993-05-18 E. R. Squibb & Sons, Inc. Indole and benzimidazole-substituted dihydropyrimidine derivatives
JPH07179456A (ja) * 1993-12-21 1995-07-18 Nkk Corp アルキルベンゾフラン誘導体及びアンジオテンシンｉｉ拮抗剤
WO2008062905A2 (en) * 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
KR20090091356A (ko) 2006-12-21 2009-08-27 화이자 프로덕츠 인코포레이티드 앤지오텐신 Ⅱ 수용체 길항작용 및 ＰＰＡＲγ 활성화 활성을 모두 갖는 화합물
KR101126383B1 (ko) 2007-02-07 2012-04-12 교와 핫꼬 기린 가부시키가이샤 3환계 화합물
WO2008096820A1 (ja) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ビフェニル誘導体
EP2151440A4 (en) 2007-05-21 2010-10-20 Takeda Pharmaceutical Heterocyclic compound and its use

Also Published As

Publication number Publication date
EP2484675A1 (en) 2012-08-08
CN102639527A (zh) 2012-08-15
KR20120095370A (ko) 2012-08-28
EP2484675A4 (en) 2013-03-06
DK2484675T3 (en) 2015-01-12
TWI500611B (zh) 2015-09-21
PT2484675E (pt) 2015-01-13
WO2011040004A1 (ja) 2011-04-07
US20120165353A1 (en) 2012-06-28
JPWO2011040004A1 (ja) 2013-02-21
TW201120028A (en) 2011-06-16
CN102639527B (zh) 2014-11-05
US8778954B2 (en) 2014-07-15
JP5583681B2 (ja) 2014-09-03
EP2484675B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
PE20160501A1 (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
DOP2010000227A (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
AR060401A1 (es) Derivados de cromen-2-ona
EA201000413A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CO6220970A2 (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos
AR085099A1 (es) Derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inhibidores de fosfodiesterasas
PE20091414A1 (es) FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR091455A1 (es) Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio
AR066605A1 (es) Derivados de heteroarilamida pirimidona
ES2721073T3 (es) Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE)
ES2557004T3 (es) Mejoras en o relacionadas con compuestos orgánicos
JP2016500653A5 (es)